...
首页> 外文期刊>Nuclear Medicine and Biology >Evaluation of novel cationic 99mTc(I)-tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging.
【24h】

Evaluation of novel cationic 99mTc(I)-tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging.

机译:评价新型阳离子99mTc(I)-三羰基配合物作为心肌灌注成像的潜在放射性示踪剂。

获取原文
获取原文并翻译 | 示例
           

摘要

This report describes the evaluation of three cationic (99m)Tc(I)-tricarbonyl complexes--[(99m)Tc(CO)(3)(L)](+) (L=N-methoxyethyl-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (ME-PNP), N-[15-crown-5)-2-yl]-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (15C5-PNP) and N-[18-crown-6)-2-yl]-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (18C6-PNP))--as potential radiotracers for myocardial perfusion imaging. Biodistribution, imaging and metabolism studies were performed using Sprague-Dawley rats. It was found that bisphosphine ligands have a significant impact on the biodistribution characteristics and clearance kinetics of their cationic (99m)Tc(I)-tricarbonyl complexes. Among the three radiotracers evaluated in this study, [(99m)Tc(CO)(3)(15C5-PNP)](+) has a very high initial heart uptake and is retained in the rat myocardium for >2 h. It also shows rapid clearance from the liver and lungs. The heart/liver ratio of [(99m)Tc(CO)(3)(15C5-PNP)](+) is approximately 2.5 times better than that of (99m)Tc-sestamibi at 30 min postinjection. [(99m)Tc(CO)(3)(15C5-PNP)](+) is almost identical to (99m)TcN-DBODC5 with respect to heart uptake, heart/lung ratio and heart/liver ratio. Results from metabolism studies show that there is no significant metabolism for [(99m)Tc(CO)(3)(15C5-PNP)](+) in the urine, but it does show a small metabolite peak (<10%) in the radio high-performance liquid chromatography chromatogram of the feces sample at 120 min postinjection. Results planar imaging studies demonstrate that [(99m)Tc(CO)(3)(15C5-PNP)](+) has a much better liver clearance profile than (99m)Tc-sestamibi and might give clinically useful images of the heart as early as 30 min postinjection. [(99m)Tc(CO)(3)(15C5-PNP)](+) is a very promising candidate for more preclinical evaluations in various animal models.
机译:该报告描述了三种阳离子(99m)Tc(I)-三羰基配合物-[[(99m)Tc(CO)(3)(L)](+)(L = N-甲氧基乙基-N,N-bis [2-(双(3-乙氧基丙基)膦基)乙基]胺(ME-PNP),N- [15-冠-5)-2-基] -N,N-双[2-(双(3-乙氧基丙基) )膦基]乙基]胺(15C5-PNP)和N- [18-冠-6)-2-基] -N,N-双[2-(双(3-乙氧基丙基)膦基)乙基]胺(18C6- PNP))–作为心肌灌注显像的潜在放射性示踪剂。使用Sprague-Dawley大鼠进行了生物分布,成像和代谢研究。发现双膦配体对其阳离子(99m)Tc(I)-三羰基配合物的生物分布特征和清除动力学具有重大影响。在这项研究中评估的三种放射性示踪剂中,[(99m)Tc(CO)(3)(15C5-PNP)](+)的初始心脏摄取量很高,并且在大鼠心肌中的保留时间超过2小时。它还显示从肝脏和肺部快速清除。注射后30分钟,[(99m)Tc(CO)(3)(15C5-PNP)](+)的心/肝比约为(99m)Tc-司他他比的2.5倍。 [(99m)Tc(CO)(3)(15C5-PNP)](+)在心脏吸收,心肺比和心肝比方面几乎与(99m)TcN-DBODC5相同。代谢研究的结果表明,尿液中[(99m)Tc(CO)(3)(15C5-PNP)](+)没有明显的代谢,但在代谢产物中确实有一个小的代谢峰(<10%)。注射后120分钟时粪便样品的无线高效液相色谱色谱图。结果平面成像研究表明[(99m)Tc(CO)(3)(15C5-PNP)](+)具有比(99m)Tc-西司他比更好的肝脏清除率特征,并可能提供临床有用的心脏图像最早在注射后30分钟。 [(99m)Tc(CO)(3)(15C5-PNP)](+)是在各种动物模型中进行更多临床前评估的非常有前途的候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号